Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707447 | 0.88 | RAB9A (0.58) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| SCHEMBL4161455 | 0.85 | RAB9A (0.54) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| Potassium Ion SCHEMBL11066423 | 0.84 | RAB9A (0.53) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| SCHEMBL18366936 | 0.81 | SMN1; SMN2 (0.52) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| SCHEMBL1912649 | 0.80 | NPC1 (0.53) | RAB9AL3MBTL1SMN1; SMN2NPC1LMNA | |
| SCHEMBL11075948 | 0.79 | ALDH1A1 (0.56) | RAB9AL3MBTL1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL24131525 | 0.77 | LMNA (0.48) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| SCHEMBL4413954 | 0.73 | RAB9A (0.65) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| SCHEMBL4414649 | 0.73 | RAB9A (0.65) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 | |
| SCHEMBL3294669 | 0.72 | RAB9A (0.50) | RAB9AL3MBTL1SMN1; SMN2NPC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| EP-3048100-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2016-07-27 | — | — | EP | disclosed |
| EP-2435402-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| CN-102448928-B | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2435402-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | RAB9A 2855/4885L3MBTL1 3409/4885SMN1; SMN2 456/4885 |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | RAB9A 2855/4885L3MBTL1 3409/4885SMN1; SMN2 456/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | RAB9A 2855/4885L3MBTL1 3409/4885SMN1; SMN2 456/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | RAB9A 3095/4885L3MBTL1 3565/4885SMN1; SMN2 1020/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | RAB9A 3095/4885L3MBTL1 3565/4885SMN1; SMN2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.